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Abstract
Background: People living with the Human Immunodeficiency Virus (PLHIV) have an increased susceptibility to develop
non-communicable diseases such as cardiovascular disease (CVD). Infection with HIV contributes to the development of
CVD independent of traditional risk factors, with endothelial dysfunction being the central physiological mechanism.
While HIV-related mortality is declining due to antiretroviral treatment (ART), the number of deaths due to CVD is rising in
South Africa - the country with the highest number of PLHIV and the world’s largest ART programme.
The EndoAfrica study was developed to determine whether HIV infection and ART are associated with cardiovascular risk
markers and changes in vascular structure and function over 18months in adults from different provinces of South Africa.
This paper describes the rationale, methodology and baseline cohort profile of the EndoAfrica study conducted in the
North West Province, South Africa.
Methods: In this case-control study, conducted between August 2017 and June 2018, 382 volunteers of African descent
(276 women; 106 men), comprising of 278 HIV infected and 104 HIV free individuals were included. We measured health
behaviours, a detailed cardiovascular profile, and performed biomarker analyses. We compared baseline characteristics,
blood pressure, vascular function and biochemical markers between those infected and HIV free.
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Results: At baseline, the HIV infected participants were older (43 vs 39 years), less were employed (21% vs 40%), less had
a tertiary education (7% vs 16%) and their body mass index was lower (26 vs 29 kg/m2) than that of the HIV free
participants. While the cardiovascular profile, flow-mediated dilation and pulse wave velocity did not differ, glycated
haemoglobin was lower (p= 0.017) and total cholesterol, high density lipoprotein cholesterol, triglycerides, gamma-
glutamyltransferase and tobacco use were higher (all p < 0.047) in PLHIV.
Conclusion: Despite PLHIV being older, preliminary cross-sectional analysis suggests that PLHIV being treated with ART do
not have poorer endothelial or vascular function compared to the HIV free participants. More detailed analyses on the
baseline and follow-up data will provide further clarity regarding the cardiovascular profile of South Africans living with HIV.
Keywords: HIV, Antiretroviral therapy, Cardiovascular risk markers, Endothelial function, Vascular function, African ancestry,
South Africa
Background
The global fight against the acquired immunodeficiency
syndrome (AIDS) epidemic has largely been successful
with the number of human immunodeficiency virus
(HIV) related deaths declining faster than the global rate
of new infections. However, much work is still required
[1]. The number of people living with HIV (PLHIV) has
grown to 37,9 million, and 800,000 of the 1,7 million
new infections in 2018 were in eastern and southern Af-
rica, which is home to 54,4% of the world’s PLHIV [1].
South Africa had approximately 7,97 million PLHIV in
2019, which is the highest number globally, with an HIV
prevalence rate of approximately 19% in adults (15–49
years) [2]. Consequently, South Africa also has the lar-
gest antiretroviral treatment (ART) programme in the
world with 62% of the adult PLHIV receiving ART [1].
Apart from the high prevalence of PLHIV, the impact of
cardiovascular disease (CVD) on the sub-Saharan African
population [3] is placing additional strain on the public
health care system. It is clear that ART has improved the
morbidity and mortality associated with HIV, however,
PLHIV are exposed to adverse cardiovascular events due to
a complex interplay between HIV, ART and CVD [4]. Car-
diovascular disease has become a common cause of death
in PLHIV as the population grows older [5]. In South Af-
rica, non-communicable disease death rates are higher than
that of HIV [6, 7], with CVD being the most prominent.
One of the main risk factors for the development of
CVD is vascular dysfunction. In PLHIV this is clearly ev-
idenced by reports of impaired endothelial (reduced
flow-mediated dilation (FMD)) [8], and vascular function
(increased large artery stiffness and decreased distensi-
bility) [9]. Furthermore, significant variations in the mi-
crovasculature, such as the retinal vascular beds [10],
increased carotid wall thickness [11] and electrocardio-
gram (ECG) abnormalities, which were predictive of in-
cident CVD [12], were reported in PLHIV.
Endothelial dysfunction is characterised by increased
endothelial permeability, leading to increased inflammatory
cytokine levels and adhesion molecule expression [13]. The
mechanisms contributing to HIV-related endothelial and
vascular dysfunction are multifaceted. This could include a
combination of a HIV induced increase in reactive oxygen
species and reduced nitric oxide bioavailability affecting
endothelium-dependent vasodilatation, direct HIV infection
of the endothelium, viral related endothelial activation, and
vascular inflammatory effects due to systemic inflammatory
cytokine or chemokine dysregulation [13–15]. Furthermore,
recent studies indicate that the HIV viral protein, gp120, re-
duces nitric oxide, and the HIV Tat protein induces endo-
thelial oxidative stress, activates apoptosis of both
endothelial cells and cardiomyocytes, and upregulates the
expression of cellular adhesion molecules [13].
It is well known that ART successfully lowers the viral
load and decreases the mortality rate, however, it is un-
clear how ART affects endothelial and vascular function.
Although treatment was associated with increased stiff-
ness [9], Solages et al. demonstrated worse endothelial
function among those with elevated levels of HIV replica-
tion [8]. Furthermore, most of the reported research was
not done in African populations; we have shown in South
Africa that HIV infection is related to increased endothe-
lial activation [16]. The odds of having increased endothe-
lial activation were more prominent in those without
treatment than in their treated counterparts [16].
Our understanding of the complex interaction be-
tween HIV and ART in the progression of CVD has im-
proved, however, more detailed exploration into the
mechanisms of HIV-induced endothelial dysfunction is
needed [13]. A better understanding of HIV-specific bio-
markers may contribute to the development or improve-
ment of guidelines, such as the European AIDS Clinical
Society guidelines, to guide health care providers in their
approach to prevent and treat CVD in PLHIV [13].
To enhance the knowledge base on HIV, ART, endo-
thelial dysfunction and CVD in South Africa, Strijdom
et al. commenced the parent EndoAfrica study titled
“Vascular endothelial dysfunction: The putative interface
of emerging cardiovascular risk factors affecting popula-
tions living with and without HIV in Sub-Saharan Africa”
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in April 2015 [17]. However, the parent EndoAfrica study ex-
ecuted in the Western Cape, South Africa, largely recruited
patients of mixed ancestry; challenging the extrapolation of
the findings to the broader South African population [17].
We expanded on the parent study by including participants
of African ancestry from the North-West province. The
North-West province leg of the EndoAfrica study,
EndoAfrica-NWU study, thus now provides an opportunity
to broaden the relevance of the findings to a larger propor-
tion of the Sub-Sahara African population.
The EndoAfrica-NWU study aims to determine
whether HIV and first-line ART regimens are associated
with CVD risk factors and changes in cardiovascular
structure and function in adults living in the North West
province of South Africa. Analyses on macro vascular
structure and micro vascular function and structure is
ongoing. Therefore, in this study, we describe the ration-
ale, methods and baseline characteristics, blood pressure,
vascular function and biochemical markers of the
EndoAfrica-NWU study.
Methods
Study design and setting
The design of the parent EndoAfrica study was discussed
in detail by Strijdom et al. [17]. The North West prov-
ince leg of the study (EndoAfrica-NWU) will adhere to
the same design as the parent study, but within a
population of African descent. The rationale for the
study is summarised in Fig. 1. The study design and set-
ting will be discussed in subsequent sections.
For the EndoAfrica-NWU study, participants were re-
cruited in and around Potchefstroom, North West prov-
ince, South Africa (Fig. 2). In 2018, South Africa’s
population was estimated at 57,73 million people of di-
verse origins and cultures. Of the total South African
population, 80,9% declared themselves to be black Afri-
cans (African ancestry), 8,8% coloured (mixed ancestry),
7,8% white and 2,5% Indian or Asian [2]. While the
mixed ancestry and white South Africans make up the
majority of the population in the Stellenbosch (Western
Cape) area where the parent EndoAfrica study was exe-
cuted, the majority of people living in the Potchefstroom
area is black South Africans (77,1% based on the 2016
census data).
Participant recruitment and eligibility
The study was approved by the Health Research
Ethics Committee of the North-West University
(NWU) (ethics number: NWU-00045-15-A1) and the
North West Department of Health. Goodwill permission
to visit the clinics was granted by the North West
Province of Health sub-district and the Potchefstroom Pa-
tient Group of the local hospital gave permission to recruit
from the clinics. Participants were recruited at seven
Fig. 1 Rational for measurements and analyses in the EndoAfrica-NWU study. HIV: human immunodeficiency virus; ART: antiretroviral treatment;
FMD: flow-mediated dilation; PWV: pulse wave velocity; IMT: intima-media thickness; DVA: dynamic vessel analysis; ECG: electrocardiography; CRP:
C-reactive protein; HbA1c: glycated hemoglobin; GGT: γ-glutamyltransferase; Hb: hemoglobin; ICAM: intercellular adhesion molecule; VCAM:
vascular cell adhesion molecule; MPO: myeloperoxidase; GDF-15: growth differentiation factor-15.
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clinics in and around Potchefstroom and at HIV support
groups by circulating leaflets (English and Setswana) as
well as by word-of-mouth.
Four hundred and forty-three volunteers (n = 443)
showed interest in the study. Eight of the interested vol-
unteers were excluded (Fig. 3) due to age, co-morbidities
or being pregnant. Thus, 435 volunteers were invited to
take part in the baseline data collection. Thirty-five of
these volunteers did not attend the day of data collection
and baseline data was collected from 400 volunteers.
Baseline data collection took place within the Hyper-
tension Research and Training clinic on the Potchef-
stroom campus of the NWU from August 2017 to June
2018. Of the 400 volunteers, 382 (276 women and 106
men) met the eligibility criteria and were included in the
study consecutively (Fig. 3). On the day of data collec-
tion participants with unknown HIV status and those
who claimed to be HIV free were counselled and
screened for HIV infection.
Study participants
Three main study groups were planned for the
EndoAfrica-NWU study based on the HIV and ART sta-
tus of participants: (i) adults (18–60 years) with HIV,
with no treatment or ≤ 4 weeks on first-line ART; (ii)
adults with HIV on first-line ART for ≥4 weeks, and (iii)
adults without HIV (controls). Of the 382 participants
included in the baseline study, 278 were HIV infected
and 104 were HIV free. Of the participants living with
HIV, only nine participants were newly diagnosed as be-
ing HIV infected or used ART for less than 4 weeks as
specified for group (i). The majority (n = 247) were on
first-line ART (Table 1) on the day of data collection,
while 22 discontinued their ART and were not using
ART on the day of data collection. The first-line fixed
dose combination ART consisted of 200mg emtricita-
bine, a nucleoside reverse transcriptase inhibitor (NRTI),
300 mg tenofovir, also a NRTI, and 600 mg Efavirenze, a
non-nucleoside reverse transcriptase inhibitor (NNRTI).
A policy of universal test-and-treat was introduced in
South Africa on 1 September 2016, making ART avail-
able to all HIV infected individuals regardless of their
cluster of differentiation 4 (CD4) T lymphocytes cell
count. Same-day initiation, advocating ART initiation on
the day of a patient’s HIV diagnosis, came into effect on
1 September 2017. As the EndoAfrica-NWU study com-
menced in mid-August 2017, these changes in the ART
policy might have affected the recruited number of
newly diagnosed patients or those that were on ART for
< 4 weeks. Receiving an HIV diagnosis and needing to
initiate ART may lead to internalized stigma (endorsing
negative beliefs and feelings about PLHIV), which is par-
ticularly high in the first weeks after the diagnosis. Inter-
nalized stigma was associated with non-initiation of
ART [18], and might also have played a role in the re-
cruitment of these individuals for the study.
Fig. 2 Data collection for the EndoAfrica-NWU study took place in Potchefstroom within the North West province, South Africa. Source of the
editable map Servier Medical Art (https://smart.servier.com/)
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During recruitment for the study we found that some
participants were defaulting (discontinuing or interrupt-
ing) their ART. Of those on ART the day of data collec-
tion (n = 247), 10% formerly interrupted their treatment
and 22 participants (8,2% of those that were on ART in
the past) were defaulting on the day of data collection.
These participants reported to “feel better” and stopped
taking their medication (ART). Defaulting ART may also
be due to the mistaken belief that they have been healed
when their viral load became undetectable [19]. Non-
adherence to ART is the most common reason for treat-
ment failure and may result in drug resistant HIV. In the
State of the Epidemic Joint United Nations Programme on
HIV/AIDS (UNAIDS) data report 2019, 67% of PLHIV in
eastern and southern Africa were on treatment, but only
58% were virally suppressed [1]. Research identified the
main determinants for non-adherence to be food insecur-
ity, use of traditional herbs and medicine, stigma, issues
with access to healthcare and disruption of services and
medication distribution in sub-Saharan Africa [20, 21].
Data collection procedures
As participants showed interest in the study and met the
inclusion criteria they were scheduled for data collection
consecutively. Six to eight participants were scheduled
per day and they were asked to fast from 22:00 the
Fig. 3 Diagram illustrating participation during the baseline data collection of the EndoAfrica-NWU studyHIV: human immunodeficiency virus;
ART: antiretroviral treatment.
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Men, n (%) 74/278 (26.6) 32/104 (30.8) 0.42
Age (years) 42.7 ± 9.13 38.9 ± 11.7 0.004
Employed, n (%) 58/275 (21.1) 42/104 (40.4) < 0.001
Education, n (%) 0.037
None 6/274 (2.19) 3/104 (2.89)
Primary 62/274 (22.6) 24/104 (23.1)
Secondary 187/274 (68.3) 60/104 (57.7)
Tertiary 19/274 (6.93) 17/104 (16.4)
Anthropometry
Waist circumference (cm) 84.7 ± 13.5 87.2 ± 15.6 0.15
Body mass index (kg/m2) 26.2 ± 7.19 28.5 ± 8.24 0.013
Cardiovascular profile
Hypertensive, n (%) a 90/278 (32.4) 44/104 (42.3) 0.070
Systolic blood pressure (mmHg) 120 ± 21.6 123 ± 18.8 0.32
Diastolic blood pressure (mmHg) 84 ± 13.1 87 ± 14.8 0.052
Heart rate (beats/min) 72 ± 13.0 71 ± 14.0 0.50
Flow-mediated dilation (%) b 7.44 (6.77;8.12) 7.23 (6.10;8.36) 0.75
Pulse wave velocity (m/s) b 7.81 (7.66;7.97) 7.72 (7.46;7.98) 0.54
Basic biochemical variables
Total cholesterol (mmol/L) 2.88 (1.71;4.42) 2.71 (1.80;4.09) 0.047
HDL (mmol/L) 1.00 (0.51;1.94) 0.89 (0.53;1.85) 0.010
LDL (mmol/L) 1.62 (0.78;2.86) 1.60 (0.86;3.07) 0.82
Triglycerides (mmol/L) 0.78 (0.35;2.16) 0.68 (0.30;1.93) 0.040
Glucose (mmol/L) 3.62 (2.75;5.11) 3.66 (2.67;7.61) 0.70
Glycated haemoglobin (%) 5.46 (4.80;6.53) 5.74 (4.90;10.5) 0.017
C-reactive protein (mg/L) 2.48 (0.25;16.1) 1.85 (0.13;20.1) 0.063
Gamma-glutamyltransferase (U/L) 51.2 (11.1;419) 22.3 (6.92;172) < 0.001
eGFR (ml/min/1.73m2) 118 (92.5;147) 122 (97.9;151) 0.055
Health behaviours
Tobacco use, n (%) 159/276 (57.6) 44/104 (42.3) 0.008
Alcohol use, n (%) 185/275 (67.3) 61/104 (58.7) 0.12
Physically active, n (%) 241/276 (87.3) 89/104 (85.6) 0.65
HIV related variables
Duration of HIV > 5 years, n (%) 171/276 (62.0) – –
CD4 count (cells/μL) 417 (68.8;1121) – –
Viral load (copies/mL) 125 (10.0;93,433) – –
Medication use
Antiretroviral therapy, n (%)
Never 9/278 (3.23) – –
Defaulted 47/278 (16.9) – –
Currently 222/278 (79.9) – –
Duration of ART > 5 years, n (%) 124/265 (46.8) – –
Anti-hypertensive, n (%) 50/278 (18.0) 26/104 (25.0) 0.13
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evening before data collection. The participants were
transported free of charge to the clinic and were fa-
miliarized with the research environment of the clinic
upon arrival at approximately 08:00. Data was col-
lected under controlled conditions. After written in-
formed consent was obtained, blood and early
morning spot urine samples were collected (Fig. 4).
All blood samples were immediately taken to the on-
site research laboratory where blood glucose levels
were determined with One Touch® Select (Johnson &
Johnson, South Africa) test strips. The blood was cen-
trifuged to obtain plasma or serum and aliquoted into
cryovials. After the urine was tested with a Combur
test strip (Roche Diagnostics, South Africa), it was
also taken to the laboratory and aliquoted into cryo-
vials. All samples were stored at − 80 °C until bio-
chemical analyses could be performed.
In parallel, a questionnaire was completed, and an-
thropometric and cardiovascular measurements (Fig. 4)
were performed. After data collection a meal was served.
Individual feedback on the immediate test results and as-
sessments were given by the registered research nurse and
the participants were referred to a local clinic or doctor if
required. The HIV status of the participants were deter-
mined with First response rapid HIV card test (Premier
Medical Corporation Limited, Daman, India) and, if posi-
tive, confirmed with a Toyo rapid test (TurkLab, Turkey).
The participants newly identified as HIV infected were re-
ferred to the clinic after counselling. After data collection
(11:30–12:30 h), the participants were transported home.
Blood samples of all the HIV infected participants were
sent to the National Health Laboratory Service for viral
load and CD4 cell count analyses. The results were taken
to the participants during personal visits at their home ad-
dress, in order for them to take it to their local clinic.
Assessments
Questionnaire
A structured medical history of participants and their
families (such as heart disease, stroke, hypertension,






Statins, n (%) 6/278 (2.16) 6/104 (5.77) 0.072
Anti-diabetic, n (%) 2/278 (0.72) 5/104 (4.81) 0.008
Anti-inflammatory, n (%) 0/278 (0.00) 1/104 (0.96) 0.10
Data are expressed as arithmetic mean ± standard deviation, geometric mean (5th and 95th percentiles) or a percentage of N
HIV human immunodeficiency virus, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, eGFR estimated glomerular filtration rate,
ART antiretroviral therapy
aSystolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg and/or use of antihypertensive medication
bAdjusted for systolic blood pressure and age, data expressed as mean (95%CI)
Fig. 4 Flow diagram of the organizational procedures during data collection in the EndoAfrica-NWU studyFMD: flow-mediated dilation; BP: blood
pressure; ECG: electrocardiogram; PWV: pulse wave velocity; IMT: carotid intima-media thickness.
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cancer and high cholesterol), lifestyle (smoking, alcohol
consumption and eating habits) and medication use
were obtained from the questionnaire.
Anthropometric measurements
Anthropometric measurements were performed accord-
ing to standardized procedures with calibrated instru-
ments and included body height (SECA 213
Stadiometer, SECA, Hamburg, Germany), body weight
(SECA 813 Electronic scale, SECA, Hamburg, Germany),
and waist and hip circumference (Lufkin steel anthropo-
metric tape, W606PM; Lufkin, Apex, USA).
Flow-mediated dilation
Flow-mediated dilation (FMD) of the brachial artery is a
non-invasive measurement technique and considered as
a gold standard to measure macrovascular endothelial
function [22]. Flow-mediated dilation is determined by
the change in brachial artery diameter in response to a
blood flow stimulus. This stimulus is created by releas-
ing an arm cuff that was inflated to a supra-systolic
blood pressure level. In response, nitric oxide (NO) is re-
leased from the endothelial cells and mediates the relax-
ation of the smooth muscle cells with subsequent
widening of the artery [23].
The FMD procedure was performed by a trained
observer, in a darkened room, while participants were
in a supine position, and after they had rested for at
least five minutes. After the procedure was explained,
participants were asked whether they exercised, had
anything to eat or drink, took any medications, or
smoked since the previous night. A blood pressure
cuff was fitted around the right forearm and the bra-
chial artery was located on the right upper arm at
around heart level. A longitudinal segment of the
right brachial artery was visualized in B-mode with a
12MHz linear probe, fixed in a single axis precision
probe holder, and an Esaote MyLab™ Five ultrasound
system (Esaote, Florence, Italy). The pulse repetition
frequency was set at 6.7 kHz, after which depth was
increased to 3 cm. After switching to pulse wave
mode, the angle of insonation was set to + 60°. Flow
velocity and diameter were continuously measured
with edge-detection and wall tracking using Cardio-
vascular Suite™ Ultrasound Edition version 2.8.1
(Quipu srl, Italy) software. Baseline diameter was ex-
amined for one minute, inflation diameter for five mi-
nutes and the post-deflation diameter for three
minutes. The software then automatically calculated
baseline diameter, maximum diameter, recovery diam-
eter, percentage FMD (the difference between baseline
and maximum diameter, expressed as a percentage of
baseline diameter), baseline shear rate and maximum
shear rate.
Blood pressure and electrocardiogram
Duplicate brachial systolic blood pressure (SBP), dia-
stolic blood pressure (DBP) and heart rate readings were
obtained from the left arm of each participant using a
validated OMRON M6 automatic digital blood pressure
monitor (Omron Healthcare, Kyoto, Japan). Resting 12-
lead ECG measurements were recorded in the supine
position using the PC-ECG 1200 (Norvav Medical Ltd.,
Kiryat Bailik, Israel) apparatus.
Pulse wave velocity
The SphygmoCor® XCEL device (AtCor Medical, Syd-
ney, Australia) was used to perform pulse wave analysis
and determine carotid-femoral pulse PWV on the right-
hand side with the participant in a supine position [24].
Pulse wave analysis was performed to produce an arterial
wave form that provided brachial pulse pressure, esti-
mated central SBP and central pulse pressure via a built-
in generalized function [25]. Pulse wave velocity was mea-
sured using the femoral artery and carotid arterial wave-
forms which were captured simultaneously. To obtain
these waveforms, an appropriate sized femoral cuff was
placed on the upper right thigh and a tonometer was
placed on the neck where the carotid pulse was felt the
strongest. To determine the pulse wave travel distance,
80% of the distance measured between the two pulsating
points (carotid-to-cuff measured using an infantometer,
and femoral-to-cuff via a tape measure) was used [26].
Measurements were performed in duplicate, and repeated
if PWV differed by more than 0.5 m/s.
Carotid wall analyses
Carotid intima-media thickness was measured non-
invasively with the General Electric Vivid E9 (GE
Vingmed Ultrasound A/S, Horten, Norway). A 3-lead
ECG was attached with two electrodes just below the
clavicles (left and right) and the third attached near the
iliac crest on the participant’s left side. A transducer was
used to obtain images and clips from two optimal angles,
on both the left and right side of the participant. The
images were then digitalized and imported into the ca-
rotid vessel analyser automated software (Vascular Re-
search Tools 6, Medical imaging applications, Coralville,
Iowa, USA). One investigator then determined carotid
wall parameters, which included intima-media thickness
and lumen diameter assessments. These parameters will
be used in subsequent calculations to determine for in-
stance cross-sectional wall area, carotid distensibility,
Young’s elastic modulus and Beta-stiffness.
Retinal imaging
Prior to retinal imaging local anaesthetic drop (Novasine
Wander 0.4% Novartis) was inserted into both eyes and
intraocular pressure was measured using a Tono-Pen
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Avia applanation tonometer (Reichert 7–0908, ISO
9001, New York, USA). Retinal imaging was not per-
formed on those with a high intraocular pressure or with
a history of epilepsy. Retinal vessel imaging/assessments
were done using the Dynamic Retinal Vessel analyser
(DVA); fitted with a Zeiss Fundus Camera FF-450 Plus
(Imedos, Jena, Germany). Images were taken 15–20min
after a drop containing 1% tropicamide and bensalco-
niumchloride 0.01% (m/v) (MYDRIACYL® 1% ophthal-
mic solution, Alcon Laboratories, South Africa) was
administered to induce mydriatic conditions in the right
eye. A colour retinal fundus image was captured by
using Visualis 2.81 software (Imedos, Jena, Germany),
with the camera angle set at 50°. The images were
exported as Tagged Image File (TIF) format and retinal
vessel calibers and pattern features such as vessel tortu-
osity, fractal analysis and lacunarity were determined
using semi-automated MONO REVA (VITO, Belgium)
software, as previously described [27].
In a subgroup of patients, dynamic retinal vessel re-
sponses to light flicker provocation were assessed. A
350 s protocol was used as described elsewhere [28]. The
primary location for these assessments were the tem-
poral superior retinal arterioles and venules located 0.5–
2.0 optic nerve head diameters from the border of the
optic nerve head. The raw numerical data generated
from the measurement was exported to an Excel tem-
plate (Microsoft), with macros. Parameters describing
the vessel dilation, constriction and recovery phases
were calculated as previously described [28].
Biological biomarkers
An array of biomarkers was analysed on site to evaluate
cardiovascular risk and endothelial function. Plasma glu-
cose levels were determined with the enzymatic reference
method with hexokinase, and glycated haemoglobin
(HbA1c) with a turbidimetric inhibition immunoassay
from haemolysed whole blood. Components of the lipid
profile, including total cholesterol (TC), high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol and triglyceride (TG) levels were determined
in serum with enzymatic colorimetric methods. Serum
apolipoproteins A-1 and B were determined with immu-
noturbidimetric assays. Liver enzymes, including alkaline
phosphatase (ALP), alanine (ALT) and aspartate amino-
transferase (AST) were determined with colorimetric
methods according to the International Federation of
Clinical Chemistry (without pyridoxal-5′-phosphate).
Gamma-glutamyltransferase (GGT) was analysed with an
enzymatic colorimetric assay in serum samples. C-reactive
protein was determined with the high-sensitivity particle
enhance turdidimetric assay, albumin with an immunotur-
bidimetric assay and creatinine with a kinetic colorimetric
assay, based on the Jaffé method, in serum samples. All of
the above mentioned, as well as urinary albumin, creatin-
ine and ions were performed on the Cobas Integra®
400plus (Roche, Basel Switzerland).
Estimated glomerular filtration rate (eGFR) was calcu-
lated with the Chronic Kidney Disease Epidemiology
(CKD-EPI) formula. Intercellular adhesion molecule-1,
vascular cell adhesion protein-1, P-selectin, myeloperoxi-
dase and growth differentiation factor-15 were deter-
mined with the Human Cardiovascular Disease
Magnetic Bead panel 2 (HCVDP2, 96-Well Plate Assay,
Luminex xMAP technology) kit on the Luminex 200 sys-
tem (EMD Millipore®, Merck, Missouri, USA).
The CD4 cell count and viral loads of the HIV infected
participants were analysed by the National Health La-
boratory Services. The CD4 cell counts were determined
using flow cytometric analysis (Beckman Coulter FC500
MPL/CellMek, Miami, FL). The Panleucogating (PLG)
method was used for CD4 T-cell enumeration and the
protocol uses a sequential automated gating strategy to
identify all CD45+ leucocytes in order to measure the
CD4% of lymphocyte and absolute CD4 count. The viral
loads were assessed by using COBAS® AmpliPrep/
COBAS® TaqMan® HIV-1 test, version 2.0. This test is a
nucleic acid amplification test for the quantification of
HIV 1 ribonucleic acid (RNA) in human plasma. The
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 test, ver-
sion 2.0 is based on three vital steps: (i) Isolation of
HIV1 RNA from specimen; (ii) reverse transcription of
RNA to complementary deoxyribonucleic acid (cDNA);
and (iii) Polymerase chain reaction (PCR) amplification
of cDNA and detection of cleaved dual labelled oligo-
nucleotide detection probe specific to the target.
Although carotid wall and retinal imaging analyses
were not available at the time of publication and do not
form part the baseline profile results in this manuscript,
the assessment methods are reported here as it forms
part of the rational of the longitudinal EndoAfrica-NWU
study.
Follow-up data collection
A follow-up assessment was done 18months after base-
line data collection to determine progression or regres-
sion of the endpoints [17].
Data management and handling
All the data generated were captured into the Research
Electronic Data Capture (REDCap) system [29]. The
baseline EndoAfrica-NWU study included 382 partici-
pants of whom 278 were HIV infected and 104 HIV free.
In a sensitivity analysis, using G*power v3.1.9.2 software
[30], we calculated that with our set group sizes, using
an alpha error of 0.05 and power of 0.95, this study
should be able to detect a medium effect size of 0.4.
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We inspected continuous variables for normality using
Q-Q plots, skewness and kurtosis. All variables with a
non-Gaussian distribution were logarithmically trans-
formed. Descriptive statistical analyses were used for
inter-group comparisons (independent t-tests, analysis of
covariance and Chi-square tests). We used IBM®, SPSS®
version 26 (IBM Corporation, Armonk, New York) soft-
ware for statistical analyses and the level for statistical
significance was set at ≤0.05.
Results
Baseline profile
The baseline profile of the participants is indicated in
Table 1. The majority of the participants were women,
representing 73% of the HIV infected and 69% of the
HIV free participants. The HIV infected participants
(n = 278) were older (43 vs 39 years), less were employed
(21% vs 40%), less had a tertiary education (9% vs 16%)
and their body mass index (BMI) was lower (26 vs 29
kg/m2) than that of the HIV free participants (n = 104).
More than half of the HIV infected participants (62%)
were living with the virus for more than five years and
47% were on ART for more than five years.
The hypertension prevalence, SBP, DBP and heart rate
did not differ between PLHIV and those free of HIV.
Furthermore, after adjusting for SBP and age, FMD
(7.44% vs 7.23%, p = 0.75) and PWV (7.81 m/s vs 7.72 m/
s, p = 0.54) also did not differ between the participants
with and without HIV. Basic biochemical analyses indi-
cated higher TC, HDL, TG and GGT and lower HbA1c
in the HIV infected group compared to the HIV free
group (all p ≤ 0.047). The PLHIV reported higher to-
bacco use (p = 0.008) than those not infected with HIV.
Discussion
The findings of the EndoAfrica-NWU study address the
knowledge gaps with regards to HIV, endothelial func-
tion and cardiovascular risk markers in South Africa.
Adults without HIV were included as a comparison
group to determine whether HIV infection and the treat-
ment thereof affects the cardiovascular disease risk
markers and vascular function of PLHIV. We included
traditional and novel biomarkers, as well as gold stand-
ard cardiovascular measurements.
Specific aspects of the baseline population profile of
our population is noteworthy. More women than men
were included as study participants, thereby a form of
bias was introduced. However, of the total number of
PLHIV older than 15 years in South Africa, an estimated
61% is women [1]. Epidemiological evidence also indi-
cated that men in sub-Saharan Africa do not access HIV
services as often as women [31], and are therefore also
less inclined to partake in a HIV-related research study.
The average age of the study population was 42 years
with PLHIV being somewhat older (43 vs 39 years). It is
well known that the incidence and prevalence of CVD
rise with age. This has also been reported previously in
an HIV infected population where comorbidities seemed
to develop earlier in PLHIV than in HIV free popula-
tions [32]. Despite that PLHIV in our study were older,
and had higher TC and TG levels, their cardiovascular
profile did not differ from those not infected. Even
though the prevalence of hypertension also did not dif-
fer, elevated BP is well documented as a risk factor for
the development of CVD, and we therefore adjusted for
both age and SBP in the preliminary analyses of the
endothelial and vascular function measurements. No dif-
ference in vascular function was observed, which was in
line with another study where we indicated endothelial
activation, but no increase in arterial stiffness in HIV in-
fected compared to HIV free Africans [16]. In the latter
study carotid dorsalis-pedis PWV was measured [16]
and not the gold standard carotid-femoral PWV as in
this study. Treatment did not seem to influence vascular
function of the infected participants of whom 40% were
on ART [16]. Nonetheless, further detailed analyses are
needed to investigate the influence of HIV/ART on ar-
terial stiffness in this study population with 79,9% of
participants on ART. Whether the differences in cardio-
vascular risk markers, such as lipid- and glycaemic
markers, GGT and tobacco use will affect the vascular
measurements also remains to be seen.
The prevalence of HIV is indicated as 19% among
adults 15–49 years old in South Africa, but the number
is higher (22%) among women in this age range [2]. Dur-
ing recruitment for our study, young people did not vol-
unteer and only 10% of the HIV infected participants in
our study were younger than 30 years of age. This is in
line with previous findings as historically, national AIDS
programs struggled to persuade young people, who often
underestimate their HIV risk, to periodically get tested
for HIV [1]. Also, low numbers of young adults enter
the ART program in South Africa, resulting in only a
small percentage of young people being virally sup-
pressed [33].
The increasing use of ART and the global obesity epi-
demic will likely accelerate the growing issues of weight
gain, obesity, diabetes and CVD in PLHIV [34]. Al-
though waist circumference did not differ between the
HIV infected and HIV free participants in our study, the
body mass index was lower (26 vs 29 kg/m2) among
those infected (79.9% on ART). As in the case of the age
differences, it remains to be determined whether adipos-
ity will affect the cardiovascular outcomes of participants
in this study.
A possible limitation of a study using FMD measure-
ments to indicate endothelial function, is the low
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reproducibility of FMD measurements due to several in-
fluencing participant-related covariates and environmen-
tal factors [23]. However, studies have shown that the
strict adherence to operating guidelines creates reliable
FMD measurements for assessing endothelial function
and cardiovascular risk [35–37]. We aimed for reprodu-
cible measurements and a low coefficient of variation for
FMD by executing the standard operating procedures
described here and in Strijdom et al. [17]. This included
extensive training of the operators, regular quality con-
trol, and measuring the same brachial artery regions. We
limited the number of FMD operators in the
EndoAfrica-NWU study by using only two well trained
researchers.
A further limitation of the study is that the recruit-
ment of our participants was based on voluntary partici-
pation constituting a convenience sample. Despite
efforts, we were unable to include more ART naïve, or
individuals who were on ART for less than 4 weeks. In
comparison to the high prevalence of HIV in South Af-
rica, this is a relatively small study population. However,
our study was performed under controlled conditions,
approximately at the same time of day, and we used gold
standard measurement techniques by a trained and ex-
perienced team of researchers in South Africa, the coun-
try with the biggest HIV epidemic in the world.
Furthermore, our study reflects current health seeking
behaviours of PLHIV in South Africa and will provide
valuable insights which will contribute to the cardiovas-
cular health of PLHIV in South Africa.
The baseline phase of the study has been completed
and the 18-month follow-up data collection was com-
pleted in December 2019. The data analyses are ongoing,
also on baseline carotid intima-media thickness and ret-
inal imaging. The data is managed by a data manager
using the RedCap system hosted at the Hypertension in
Africa Research Team (HART), North West University,
as well as the Department of Biomedical Sciences, Stel-
lenbosch University (as part of the parent study).
Conclusion
The EndoAfrica-NWU study addresses the lack of, and
need for, research with regards to a detailed cardiovascu-
lar risk profile among South Africans living with HIV, in
the epicentre of the global epidemic. While detailed ana-
lyses are still ongoing, the baseline profile of current
data indicates no difference in the cardiovascular profile,
including endothelial and vascular function measure-
ments, despite the fact that the PLHIV were older. This
study will generate knowledge unique to the South Afri-
can HIV infected population and has the potential to
lead to novel strategies to promote the cardiovascular
health of this vulnerable population throughout Sub-
Saharan Africa.
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